Search

Your search keyword '"Brunton, Bethany"' showing total 16 results
Start Over Author "Brunton, Bethany"
16 results on '"Brunton, Bethany"'

1. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

Author

Cook, Joselle, Peng, Kah-Whye, Witzig, Thomas E., Broski, Stephen M., Villasboas, Jose C., Paludo, Jonas, Patnaik, Mrinal, Rajkumar, Vincent, Dispenzieri, Angela, Leung, Nelson, Buadi, Francis, Bennani, Nora, Ansell, Stephen M., Zhang, Lianwen, Packiriswamy, Nandakumar, Balakrishnan, Baskar, Brunton, Bethany, Giers, Marissa, Ginos, Brenda, Dueck, Amylou C., Geyer, Susan, Gertz, Morie A., Warsame, Rahma, Go, Ronald S., Hayman, Suzanne R., Dingli, David, Kumar, Shaji, Bergsagel, Leif, Munoz, Javier L., Gonsalves, Wilson, Kourelis, Taxiarchis, Muchtar, Eli, Kapoor, Prashant, Kyle, Robert A., Lin, Yi, Siddiqui, Mustaqeem, Fonder, Amie, Hobbs, Miriam, Hwa, Lisa, Naik, Shruthi, Russell, Stephen J., and Lacy, Martha Q.

Published
2022
Full Text
View/download PDF

2. Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210.

Author

Li, Roger, Ku, Ja Hyeon, Vilaseca Cabo, Antoni, Guerrero-Ramos, Félix, Meeks, Joshua J, Beeharry, Neil, Quiroz, Michelle, Zhang, Jiarui, Smirnov, Denis, Rajpurohit, Yashoda Rani, Brunton, Bethany, Martinez, Gabriela, Cost, Carrye Rudolph, Kalota, Anna, Lauring, Josh David, Stone, Nicole L., Thomas, Shibu, Jia, Shidong, Kim, Il-Jin, and Du, Pan

Published
2024
Full Text
View/download PDF

4. An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)

Author

Cook, Joselle, primary, Peng, Kah-Whye, additional, Witzig, Thomas E., additional, Broski, Stephen, additional, Villasboas, Jose C., additional, Paludo, Jonas, additional, Patnaik, Mrinal M., additional, Rajkumar, S. Vincent, additional, Dispenzieri, Angela, additional, Leung, Nelson, additional, Buadi, Francis K., additional, Bennani, N. Nora, additional, Ansell, Stephen M., additional, Zhang, Lianwen, additional, Pakiriswamy, Nandakumar, additional, Balakrishnan, Baskar, additional, Brunton, Bethany, additional, Giers, Marissa, additional, Ginos, Brenda F, additional, Dueck, Amylou C., additional, Geyer, Susan M., additional, Gertz, Morie A., additional, Warsame, Rahma M, additional, Go, Ronald, additional, Hayman, Suzanne R., additional, Dingli, David, additional, Kumar, Shaji, additional, Bergsagel, P. Leif, additional, Gonsalves, Wilson I, additional, Kourelis, Taxiarchis, additional, Muchtar, Eli, additional, Kapoor, Prashant, additional, Kyle, Robert A., additional, Lin, Yi, additional, Siddiqui, Mustaqeem A., additional, Fonder, Amie, additional, Hobbs, Miriam A., additional, Hwa, Yi L., additional, Russell, Stephen J., additional, and Lacy, Martha Q., additional

Published
2021
Full Text
View/download PDF

5. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Author

Vandergaast, Rianna, primary, Carey, Timothy, additional, Reiter, Samantha, additional, Lathrum, Chase, additional, Lech, Patrycja, additional, Gnanadurai, Clement, additional, Haselton, Michelle, additional, Buehler, Jason, additional, Narjari, Riya, additional, Schnebeck, Luke, additional, Roesler, Anne, additional, Sevola, Kara, additional, Suksanpaisan, Lukkana, additional, Bexon, Alice, additional, Naik, Shruthi, additional, Brunton, Bethany, additional, Weaver, Scott C., additional, Rafael, Grace, additional, Tran, Sheryl, additional, Baum, Alina, additional, Kyratsous, Christos A., additional, Peng, Kah Whye, additional, and Russell, Stephen J., additional

Published
2021
Full Text
View/download PDF

6. Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2

Author

Vandergaast, Rianna, primary, Carey, Timothy, additional, Reiter, Samantha, additional, Lech, Patrycja, additional, Gnanadurai, Clement, additional, Tesfay, Mulu, additional, Buehler, Jason, additional, Suksanpaisan, Lukkana, additional, Naik, Shruthi, additional, Brunton, Bethany, additional, Recker, Jordan, additional, Haselton, Michelle, additional, Ziegler, Christopher, additional, Roesler, Anne, additional, Mills, John R., additional, Theel, Elitza, additional, Weaver, Scott C., additional, Rafael, Grace, additional, Roforth, Matthew M., additional, Jerde, Calvin, additional, Tran, Sheryl, additional, Diaz, Rosa Maria, additional, Bexon, Alice, additional, Baum, Alina, additional, Kyratsous, Christos A., additional, Peng, Kah Whye, additional, and Russell, Stephen J., additional

Published
2020
Full Text
View/download PDF

7. Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection

Author

Rogers, Kai J, primary, Shtanko, Olena, additional, Stunz, Laura L, additional, Mallinger, Laura N, additional, Arkee, Tina, additional, Schmidt, Megan E, additional, Bohan, Dana, additional, Brunton, Bethany, additional, White, Judith M, additional, Varga, Steve M, additional, Butler, Noah S, additional, Bishop, Gail A, additional, and Maury, Wendy, additional

Published
2020
Full Text
View/download PDF

8. Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.

Author

Leibovich, Bradley C., primary, Miest, Tanner, additional, Young, Paul R, additional, Gonzalgo, Mark L., additional, Boorjian, Stephen A., additional, Tollefson, Matthew K., additional, Karnes, R. Jeffrey, additional, Frank, Igor, additional, Lyon, Timothy D., additional, Kroeninger, Tessa, additional, Naik, Shruthi, additional, Reckner, Monica, additional, Diaz, Rosa M, additional, Kaesshaefer, Stephen, additional, Whitelaw, Ena, additional, Brunton, Bethany A, additional, Newsom, Alysha, additional, Packiriswamy, Nandakumar, additional, Peng, Kah Whye, additional, and Bexon, Alice Susannah, additional

Published
2020
Full Text
View/download PDF

10. Abstract CT090: Rational design of an oncolytic virus permits use of interferon beta as a pharmacodynamic marker for clinical application

Author

Cripe, Timothy P., primary, Bakkum-Gamez, Jamie, additional, Merchan, Jaime R., additional, Lacy, Martha Q., additional, Patel, Manish R., additional, Powell, Steven, additional, Strauss, James, additional, Zhang, Lianwen, additional, Sakuma, Toshie, additional, Diaz, Memy, additional, Packiriswamy, Nandakumar, additional, Upreti, Deepak, additional, Brunton, Bethany, additional, Jevremovic, Dragan, additional, Russell, Stephen J., additional, Bexon, Alice, additional, and Peng, Kah-Whye, additional

Published
2019
Full Text
View/download PDF

13. Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection.

Author

Rogers, Kai J., Shtanko, Olena, Stunz, Laura L., Mallinger, Laura N., Arkee, Tina, Schmidt, Megan E., Bohan, Dana, Brunton, Bethany, White, Judith M., Varga, Steve M., Butler, Noah S., Bishop, Gail A., and Maury, Wendy

Subjects
VIRUS diseases, RNA viruses, VIRAL replication, EBOLA virus, VESICULAR stomatitis
Abstract

Many acute viral infections target tissue Mϕs, yet the mechanisms of Mϕ‐mediated control of viruses are poorly understood. Here, we report that CD40 expressed by peritoneal Mϕs restricts early infection of a broad range of RNA viruses. Loss of CD40 expression enhanced virus replication as early as 12–24 h of infection and, conversely, stimulation of CD40 signaling with an agonistic Ab blocked infection. With peritoneal cell populations infected with the filovirus, wild‐type (WT) Ebola virus (EBOV), or a BSL2 model virus, recombinant vesicular stomatitis virus encoding Ebola virus glycoprotein (rVSV/EBOV GP), we examined the mechanism conferring protection. Here, we demonstrate that restricted virus replication in Mϕs required CD154/CD40 interactions that stimulated IL‐12 production through TRAF6‐dependent signaling. In turn, IL‐12 production resulted in IFN‐γ production, which induced proinflammatory polarization of Mϕs, protecting the cells from infection. These CD40‐dependent events protected mice against virus challenge. CD40−/− mice were exquisitely sensitive to intraperitoneal challenge with a dose of rVSV/EBOV GP that was sublethal to CD40+/+ mice, exhibiting viremia within 12 h of infection and rapidly succumbing to infection. This study identifies a previously unappreciated role for Mϕ‐intrinsic CD40 signaling in controlling acute virus infection. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

14. Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer

Author

Bakkum-Gamez, Jamie, primary, Block, Matthew S., additional, Packiriswamy, Nanda, additional, Brunton, Bethany A., additional, Deepak, Upreti, additional, Mitchell, Jonathan M., additional, Suksanpaisan, Lukkana, additional, Atherton, Pamela, additional, Dueck, Amylou, additional, Russell, Stephen J., additional, Lacy, Martha Q., additional, and Peng, Kah-Whye, additional

Published
2018
Full Text
View/download PDF

15. Abstract CT051: Preliminary correlative and clinical data from a first-in-human (FIH) study of the intratumoral (IT) oncolytic virotherapy, Voyager-V1, in patients with solid tumors

Author

Powell, Steven, primary, Patel, Manish R., additional, Merchan, Jaime R., additional, Cripe, Timothy P., additional, Strauss, James, additional, Diaz, Rosa M., additional, Packiriswamy, Nandakumar, additional, Brunton, Bethany A., additional, Upreti, Deepak, additional, Khan, Rehan, additional, Suksanpaisan, Lukkana, additional, Vandergaast, Rianna, additional, Russell, Stephen J., additional, Bexon, Alice S., additional, and Peng, Kah Whye, additional

Published
2018
Full Text
View/download PDF

16. Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.

Author

Vandergaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, Buehler J, Suksanpaisan L, Naik S, Brunton B, Recker J, Haselton M, Ziegler C, Roesler A, Mills JR, Theel E, Weaver SC, Rafael G, Roforth MM, Jerde C, Tran S, Diaz RM, Bexon A, Baum A, Kyratsous CA, Peng KW, and Russell SJ

Abstract

We here describe the development and validation of IMMUNO-COV™, a high-throughput clinical test to quantitatively measure SARS-CoV-2-neutralizing antibodies, the specific subset of anti-SARS-CoV-2 antibodies that block viral infection. The test measures the capacity of serum or purified antibodies to neutralize a recombinant Vesicular Stomatitis Virus (VSV) encoding the SARS-CoV-2 spike glycoprotein. This recombinant virus (VSV-SARS-CoV-2-S-Δ19CT) induces fusion in Vero cell monolayers, which is detected as luciferase signal using a dual split protein (DSP) reporter system. VSV-SARS-CoV-2-S-Δ19CT infection was blocked by monoclonal α-SARS-CoV-2-spike antibodies and by plasma or serum from SARS-CoV-2 convalescing individuals. The assay exhibited 100% specificity in validation tests, and across all tests zero false positives were detected. In blinded analyses of 230 serum samples, only two unexpected results were observed based on available clinical data. We observed a perfect correlation between results from our assay and 80 samples that were also assayed using a commercially available ELISA. To quantify the magnitude of the anti-viral response, we generated a calibration curve by adding stepped concentrations of α-SARS-CoV-2-spike monoclonal antibody to pooled SARS-CoV-2 seronegative serum. Using the calibration curve and a single optimal 1:100 serum test dilution, we reliably measured neutralizing antibody levels in each test sample. Virus neutralization units (VNUs) calculated from the assay correlated closely (p < 0.0001) with PRNT EC50 values determined by plaque reduction neutralization test against a clinical isolate of SARS-CoV-2. Taken together, these results demonstrate that the IMMUNO-COV™ assay accurately quantitates SARS-CoV-2 neutralizing antibodies in human sera and therefore is a potentially valuable addition to the currently available serological tests. The assay can provide vital information for comparing immune responses to the various SARS-CoV-2 vaccines that are currently in development, or for evaluating donor eligibility in convalescent plasma therapy studies.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results